PRODUCT INFORMATION

FH535

Item No. 18001

CAS Registry No.:	108409-83-2
Formal Name:	2,5-dichloro-N-(2-methyl-4-nitrophenyl)-benzenesulfonamide
MF:	$C_{13}H_{10}Cl_2N_2O_4S$
FW:	361.2
Purity:	≥95%
UV/Vis.:	λ_{max}: 292 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FH535 is supplied as a crystalline solid. A stock solution may be made by dissolving the FH535 in the solvent of choice, which should be purged with an inert gas. FH535 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of FH535 in these solvents is approximately 10 and 25 mg/ml, respectively.

FH535 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, FH535 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. FH535 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

FH535 is an inhibitor of β-catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPARγ and PPARδ.[1] At 15 µM, FH535 blocks the recruitment of β-catenin and GRIP1 to PPARγ and PPARδ.[1] Presumably through these actions, FH535 is selectively toxic to some carcinoma cell lines expressing the Wnt/β-catenin pathway.[1] FH535 is used to study the role of Wnt/β-catenin pathway in various cancer cell lines.[2-4]

References

1. Handeli, S. and Simon, J.A. A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities. *Mol. Cancer Ther.* **7(3)**, 521-529 (2008).
2. Faisy, C., Grassin-Delyle, S., Blouquit-Laye, S., *et al*. Wnt/β-catenin signaling modulates human airway sensitization induced by β_2-adrenoceptor stimulation. *PLoS One* **9(10)**, (2014).
3. Su, H., Jin, X., Zhang, X., *et al*. FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R. *J. Transl. Med.* **13:104**, (2015).
4. Wu, M.-Y., Liang, R.-R., Chen, K., *et al*. FH535 inhibited metastasis and growth of pancreatic cancer cells. *OncoTargets and Therapy* **8**, 1651-1670 (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM